Arx reaps 3.6x on DCB trade sale

The divestment generated an overall cash-on-cash return of 3.6x and an IRR of more than 25%.

Arx acquired DCB in 2015, via its €102m Arx CEE III fund. The GP is currently investing from its fourth vehicle, which closed on €95m in October 2017. The fund targets small- and mid-sized companies based across central and eastern Europe, operating in a wide range of sectors.

Arx CEE IV is currently almost 50% deployed and the GP expects to start fundraising for a fifth vehicle in 2021.

Under Arx's ownership, DCB boosted its growth both organically and by completing four strategic add-ons. The company doubled its revenues from €7m in 2015 to €14m in 2019 and consolidated its market position in the Slovenian healthcare sector.

Company
Established in 1992 and headquartered in Bled, DCB provides healthcare services including medical examinations like MRI scans, specialising in gastroenterology and urology. The business operates six centres and performs more than 20,000 examinations per year.

People
Arx Equity Partners – Brian Wardrop (managing partner).
Diagnosticni Center Bled – Zvone Novina (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• CEE
• Healthcare
• Arx Equity Partners
• Slovenia
• Trade sale